Off label use of antimalarials in covid-19 patients

Authors

  • Erivan de Souza Oliveira Universidade de Fortaleza
  • Marcela Feitosa Matos Universidade Estadual do Ceará
  • Olga Samara Silva Cavalcante Universidade de Fortaleza
  • Arlandia Cristina Lima Nobre de Morais Universidade de Fortaleza (UNIFOR)

DOI:

https://doi.org/10.33448/rsd-v9i6.3517

Keywords:

Chloroquine; Coronavirus; Hydroxychloroquine; Treatment.

Abstract

This study aimed to verify the level of scientific evidence on the off label use of chloroquine and hydroxychloroquine for the treatment of patients with covid-19 in scientific productions published in renowned international journals. It is an integrative literature review, of an exploratory nature, with a qualitative approach. To compose the corpus of final analysis, 5 articles were selected that met the eligibility criteria established for the study. Through the works highlighted in this article, it is possible to observe that the drugs under study have promising results against covid-19 and can help prevent the progression of the disease to a critical state. It was observed that there were adverse reactions considered mild in two patients being treated with hydroxychloroquine, but no side effects considered serious. Caution is recommended when using these drugs, as they can cause adverse effects.

References

Anvisa (2020). Hidroxicloroquina e cloroquina viram produtos controlados. Acesso em 04 de abril de 2020, em http://portal.anvisa.gov.br/noticias/-/asset_publisher/fxrpx9qy7fbu/content/hidroxicloroquina-vira-produto-controlado/219201/pop_up?_101_instance_fxrpx9qy7fbu_viewmode=print&_101_instance_fxrpx9qy7fbu_languageid=pt_br

Bing (2020). Rastreador de COVID-19. Acesso em 19 de abril de 2020, em: https://bing.com/covid

Browning, D. J. (2014). Hydroxychloroquine and Chloroquine Retinopathy. Springer (Ed.), Pharmacology of Chloroquine and Hydroxychloroquine (pp. 35-53).

Camacho, A. C. L. F., Joaquim, F. L., Menezes, H. F., & Anna, R. M. S. (2020). A tutoria na educação à distância em tempos de COVID-19: orientações relevantes. Research, Society and Development, 9(5),1-12.

Chen, Z., Hu, J., Zhang, Z., Jiang, S., Han, S., & Yan, D., et al. (2020). Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv, doi: 10.1101/2020.03.22.20040758

Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., & Bondi-Zoccai, G., et al. (2020). Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. Journal of the American College of Cardiology, doi: 10.1016/j.jacc.2020.03.031.

Fang, L., Karakiulakis, G., & Roth, M. (2020). Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. The Lancet Respiratory Medicine. doi:10.1016/s2213-2600(20)30116-8.

Fiocruz (2020). Covid-19: Fiocruz Amazônia conclui o primeiro sequenciamento do vírus na região Norte. Acesso em 01 de abril de 2020, em: https://portal.fiocruz.br/noticia/covid-19-fiocruz-amazonia-conclui-o-primeiro-sequenciamento-do-virus-na-regiao-norte.

Fiocruz (2020). Fiocruz lidera no Brasil ensaio clínico 'Solidarity' (Solidariedade) da OMS. Acesso em 04 de abril de 2020, em: https://portal.fiocruz.br/noticia/fiocruz-lidera-no-brasil-ensaio-clinico-solidarity-solidariedade-da-oms

Fiocruz (2020). Fiocruz inclui primeiro paciente no ensaio clínico "Solidarity". Acesso em 04 de abril de 2020, em: https://portal.fiocruz.br/noticia/fiocruz-inclui-primeiro-paciente-no-ensaio-clinico-solidarity

Gautret, P., Lagier, J. C., Parola, P., Hoang, V. T., Meddeb, L., & Mailhe, M., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Journal Pre-proof. doi: doi.org/10.1016/j.ijantimicag.2020.105949.

Liu, J., Cao, R., Xu, M., Mang, X., Zhang, H., & Hu, H., et al. (2020). Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery, 6:16. doi: 10.1038/s41421-020-0156-0

Menegatti, R., Fraga, C. A. M., & Barreiro, E. L. (2001). A importância da síntese de Fármacos. Cadernos Temáticos de Química Nova na Escola, 3,16-22.

Ministério da Saúde (2020). Uso da Cloroquina como terapia adjuvante no tratamento de formas graves do COVID-19. Acesso em 29 de março de 2020, em: https://cdn.oantagonista.net/uploads/2020/03/nota_cloroquina.pdf

Oliveira, E. S., & Morais, A. C. L. N. (2020). Covid-19: uma pandemia que alerta à população. Interamerican Journal Of Medicine And Health, 3,1-7. doi: 10.31005/iajmh.v3i0.80

OPAS (2020). OMS afirma que COVID-19 é agora caracterizada como pandemia. Acesso em 01 de abril de 2020, em: https://www.paho.org/bra/index.php?option=com_content&view=article&id=6120:oms-afirma-que-covid-19-e-agora-caracterizada-como-pandemia&Itemid=812

Touret, F., & Lamballerie, X. (2020). Of chloroquine and COVID-19. Antiviral Res. doi: 10.1016/j.antiviral.2020.104762

Wang, M., Cao, R., Zhang, L., Yang, X., Liu, J., & Xu, M., et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research, 30, 269–271. doi: 10.1038/s41422-020-0282-0

Whittemore, R., & Knafl, K. (2005). The integrative review: Updated methodology. J. Adv. Nurs, 52(5), 546–553.

Yao, X., Ye, F., Zhang, M., Cui, C., Huang, B., & Niu, P., et al. (2020). In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases, doi: 10.1093/cid/ciaa237

Zhang, H., Penninger, J. M., Li, Y., Zhong, N., & Slutsky, A. S. (2020). Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. doi: 10.1007/s00134-020-05985-9.

Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y. D., Yang, Y. B., & Yan, Y. Q., et al. (2020). Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China. Allergy. doi:10.1111/all.14238

Downloads

Published

21/04/2020

How to Cite

OLIVEIRA, E. de S.; MATOS, M. F.; CAVALCANTE, O. S. S.; MORAIS, A. C. L. N. de. Off label use of antimalarials in covid-19 patients. Research, Society and Development, [S. l.], v. 9, n. 6, p. e168963517, 2020. DOI: 10.33448/rsd-v9i6.3517. Disponível em: https://www.rsdjournal.org/index.php/rsd/article/view/3517. Acesso em: 18 apr. 2024.

Issue

Vol. 9 No. 6

Section

Health Sciences

License

Authors who publish with this journal agree to the following terms:

1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.